
What Is the Ceiling for IONQ Stock?
IonQ (NYSE:IONQ) is a quantum computing startup that, like many…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
Income Statement | ||||||
Revenue | $10.1B | $9.7B | $9.8B | $2.3B | $2.4B | |
Gross Profit | $7.9B | $7.3B | $7.4B | $1.7B | $1.8B | |
Operating Income | $2.8B | $1.9B | $2.3B | $577.5M | $625.2M | |
EBITDA | $4.5B | $2.1B | $2.7B | $681.5M | $554.4M | |
Diluted EPS | $21.54 | $8.01 | $10.13 | $2.70 | $1.64 |
Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $6.7B | $7.9B | $9.8B | $6.8B | $7.6B | |
Total Assets | $23.9B | $23.6B | $24.6B | $26.6B | $28B | |
Current Liabilities | $3.2B | $3.9B | $3B | $3.2B | $5.3B | |
Total Liabilities | $13.2B | $12.4B | $10.8B | $11.4B | $11.1B | |
Total Equity | $10.7B | $11.2B | $13.8B | $15.2B | $17B | |
Total Debt | $7.3B | $7.3B | $6.3B | $6.5B | $6.3B |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | $1.7B | $1.6B | $2.6B | $553.2M | $259.3M | |
Cash From Investing | $1.3B | -$3.2B | -$780.5M | -$66M | -$47.3M | |
Cash From Financing | -$1.8B | -$246.9M | -$266.9M | -$439.6M | -$23M | |
Free Cash Flow | $1.4B | $1.3B | $2.3B | $432.3M | $212.2M |
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
In the current month, BIIB has received 13 Buy ratings 18 Hold ratings, and 1 Sell ratings. The BIIB average analyst price target in the past 3 months is $171.89.
According to analysts, the consensus estimate is that Biogen share price will rise to $171.89 per share over the next 12 months.
Analysts are divided on their view about Biogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biogen is a Sell and believe this share price will drop from its current level to $115.00.
The price target for Biogen over the next 1-year time period is forecast to be $171.89 according to 32 Wall Street analysts, 13 of them rate the stock a Buy, 1 rates the stock a Sell, and 18 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Biogen is a Hold. 18 of 32 analysts rate the stock a Hold at this time.
You can purchase shares of Biogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biogen shares.
Biogen was last trading at $134.16 per share. This represents the most recent stock quote for Biogen. Yesterday, Biogen closed at $134.21 per share.
In order to purchase Biogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
IonQ (NYSE:IONQ) is a quantum computing startup that, like many…
TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…
When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…
Market Cap: $4T
P/E Ratio: 56x
Market Cap: $3.7T
P/E Ratio: 42x
Market Cap: $3.2T
P/E Ratio: 35x
MP Materials [MP] is down 0.31% over the past day.
Newegg Commerce [NEGG] is up 74.03% over the past day.
United Airlines Holdings [UAL] is down 4.35% over the past day.